NCT04637919View on ClinicalTrials.gov

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2020

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hand, Foot and Mouth Disease
Interventions
BIOLOGICAL

IN-B001 EV71 A dose

Inactivated vaccine against EV71, three doses, 28 days interval

BIOLOGICAL

IN-B001 CVA16 B dose

Inactivated vaccine against CVA16, three doses, 28 days interval

BIOLOGICAL

IN-B001 Bivalent C dose

Inactivated vaccine against EV71/CVA16, three doses, 28 days interval

BIOLOGICAL

Placebo

Placebo, three doses, 28 days interval

Trial Locations (1)

Unknown

Seoul National University Hospital, Clinical Trial Center, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY